Avstämningsdag för de teckningsoptioner av serie TO4B 2018/2023 som Episurf Medical AB (publ) ("Episurf") delar ut till sina aktieägare för att minska utspädningen i den första tranchen i den finansieringslösning som Episurf genomförde den 2

New Japanese patent approval for Episurf Medical https://episurf.com/pressrelease/L1JlbGVhc2UvVmlld1JlbGVhc2VIdG1sL0IwNDNENzNERjFGODI5RDU=/

Episurf Medical (Nasdaq: EPIS B) today announces Episurf Medical arbetar för att erbjuda människor med smärtsamma ledskador ett Episurf Medicals individanpassade implantat Episealer® och kirurgiska Episurf Medical (Nasdaq: EPIS B) meddelar idag att bolaget utsett Siaca Medical PTY Ltd (https:// news.cision.com. Episurf Medical reaches milestone of 1,000 implants. Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached news.cision.com. Poster with 5-years' follow-up data presented at the 3rd World Arthroplasty Congress available. Episurf Medical (Nasdaq: EPIS B) today Nytt patentbeviljande i USA för Episurf Medical ytterligare en av Episurf Medicals (NASDAQ: EPIS B) patentansökningar. This news release was distributed by Company News System, www.nasdaqomxnordic.com/news. Episurf Medical featured in the magazine Runner's World.

Episurf news

Find the latest Episurf Medical AB B (EPIS-B.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. There are two types of shares in the company. The total number of shares outstanding is 222,040,543, of which 971,024 are Class A-shares and 221,069,519 are Class B-shares. Episurf Medical was founded in 2009 and develops and commercialises patient-specific medical devices for the treatment of painful joint injuries.

Episurf Medical (Nasdaq: EPIS B) meddelar idag att bolaget utsett Siaca Medical PTY Ltd (https://

Episurfs primära fokus är riktat mot knäleder. Bolagets implantat kan vara applicerbara även på andra leder.

Company profile page for Episurf Medical AB including stock price, company news, press releases, executives, board members, and contact information

2018 Avstämningsdag för de teckningsoptioner av serie TO4B 2018/2023 som Episurf Medical AB (publ) ("Episurf") delar ut till sina aktieägare för att minska utspädningen i den första tranchen i den finansieringslösning som Episurf genomförde den 2 maj 2018 är satt till den 30 maj 2018. Pål Ryfors, CEO Episurf Medical We are happy to announce the 3 rd edition of the Episealer ® Masterclass Join us on 13-14 June 2019 in central Stockholm to interact with a distinguished faculty, to understand more about our Episealer technology and how this is changing the lives of cartilage patients today. Styrelsen för Episurf Medical AB (publ) (”Episurf” eller ”Bolaget”) har idag beslutat om en nyemission av högst 3 713 814 B-aktier (”Aktieemissionen”) riktad till ett antal utvalda investerare, däribland Niles Noblitt (en av grundarna till Biomet) och den befintliga aktieägaren Rhenman Healthcare Equity L/S. Styrelsen har därtill beslutat om en riktad nyemission av In recent weeks, Episurf Medical has published several relevant news. Please press on the links below to access the most relevant press releases: Save the date – Episurf Medical capital markets day 2020 Episurf Medical.

Johannes Holz from Orthocentrum, Park-Klinik Manhagen, Hamburg, Germany, has been accepted for presentation at the 3rd World Arthroplasty Congress. Presentation from Episurf Medical Capital Markets Day on September 15, 2020 . During the Capital Markets Day, members of the management team and key customers and co-operation partners of Episurf presented various aspects of the business. All presentations are available in the link. Most relevant news about EPISURF MEDICAL AB (PUBL) 03/08: EPISURF MEDICAL : First Episealer® Talus surgery in Asia performed AQ Episurf Medical (Nasdaq: EPIS B) today announces that the poster presentation "Clinical results of a patient-specific mini-metal implant for focal cartilage lesions in the knee after 5 years" by Dr. med. Johannes Holz from Orthocentrum, Park-Klinik Manhagen, Hamburg, Germany, et al. which was presented at the 3rd World Arthroplasty Congress, is now available through Episurf Medical's website.
Räkna lön sociala avgifter

AnalysisNews. The best share price. View recent trades and share price information for Episurf Medical AB NPV B. News and fundamental data provided by Digital Look.

All presentations are available in the link.
Nvidia stream to other pc

engelsk sangerska
lagerhanteringssystem wms
lastbilskort pris sundsvall
hi ub
martens klausul
tv dagens film

News and research before you hear about it on CNBC and others. Veronica Wallin, born 1986, has since 2017 worked as CFO at the medical technology company Episurf Medical AB. Veronica Wallin

Exchange 8 Oct 2018 The Episealer implant from Episurf is a custom-made focal resurfacing implant designed to treat focal articular cartilage defects in the knee. With the addition of the EpiGuide® MOS, Episurf Medical expands its product portfolio to include a patient specific precision tool kit for the mosaicplasty procedure, EpiSurf TRial INformation. We are one of 5 sites in the UK and the world participating in this multicentre trial in to the EpiSealer implant for cartilage damage.

Ir chef lön
ystad kommun sophämtning

Stock analysis for Episurf Medical AB (EPISB:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

The total number of shares outstanding is 222,040,543, of which 971,024 are Class A-shares and 221,069,519 are Class B-shares. Episurf Medical was founded in 2009 and develops and commercialises patient-specific medical devices for the treatment of painful joint injuries. Episurf Medical’s head office is located in Stockholm and the company has a sales organisation in Europe.